India Globalization Capital, Inc. (NYSE: IGC) Announces Alzheimer’s Drug Candidate Targeting Aβ Proteins
More than 5.3 million people in the U.S. have Alzheimer’s disease, which has no effective cure or substantial treatment India Globalization Capital’s IGC-ADI drug candidate targets proteins associated with the buildup of lesions in the brain The company acquired exclusive rights to a patent, based on University of South Florida studies supporting THC’s role in inhibiting Aβ plaque production Alzheimer’s disease now affects over 5.3 million people in the United States, imposing an estimated economic cost of $236 billion. There has been no effective treatment to slow down or reverse its effects. That may be about to change, as India…